Three-dimensional telomere signatures of Hodgkin- and Reed-Sternberg cells at diagnosis identify patients with poor response to conventional chemotherapy

Translational Oncology

Volumn 5, Issue 4, 2012, Pages 269-277

  Knecht, Hans ^a,b   Kongruttanachok, Narisorn ^b   Sawan, Bassem ^a   Brossard, Josée ^a   Prévost, Sylvain ^a   Turcotte, Eric ^a   Lichtensztejn, Zelda ^b   Lichtensztejn, Daniel ^b   Mai, Sabine ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 1;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MALE; MONONUCLEAR CELL; REED STERNBERG CELL; RETROSPECTIVE STUDY; TELOMERE; TELOMERE SHORTENING; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE;

EID: 84865519425     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12142     Document Type: Article

References (45)

1. LeBel C and Wellinger RJ (2005). Telomeres: what's new at your end? J Cell Science 118, 2787-2788.
2. De Lange T (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Gene Dev 19, 2100-2110.
3. Hug N and Lingner J (2006). Telomere length homeostasis. Chromosoma 115, 413-425.
4. DePinho RA and Polyak K (2004). Cancer chromosomes in crisis. Nat Genet 36, 932-934.
5. Landsdorp PM (2009). Telomeres and disease. EMBO J 28, 2532-2540.
6. Chuang TC, Moshir S, Garini Y, Chuang AYC, Young IT, Vermolen B, van den Doel R, Mougey V, Perrin M, Braun M, et al. (2004). The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol 2, 12.
7. Mai S and Garini Y (2005). Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. Cell Cycle 4, 1327-1331.
8. Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztein Z, Kuttler F, Chuang TC, Moshir S, Mougey V, et al. (2005). C-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci USA 102, 9613-9618.
9. Mai S and Garini Y (2006). The significance of telomeric aggregates in the interphase nuclei of tumor cells. J Cell Biochem 97, 904-915.
10. Mai S (2010). Initiation of telomere-mediated chromosomal rearrangements in cancer. J Cell Biochem 109, 1095-1102.
11. Knecht H and Mai S (2011). 3D imaging of telomeres and nuclear architecture: an emerging tool of 3D nano-morphology based diagnosis. J Cell Physiol 226, 859-867.
12. Hsu SM, Zhao X, Chakraborty S, Liu YF, Whang-Peng J, Lok MS, and Fukuhara S (1988). Reed-Sternberg cells in Hodgkin's cell lines HDLM, L-428, and KM-H2 are not actively replicating: lack of bromodeoxyuridine uptake by multinuclear cells in culture. Blood 71, 1382-1389.
13. Drexler HG, Gignac SM, Hoffbrand AV, and Minowada J (1989). Formation of multinucleated cells in a Hodgkin's-disease-derived cell line. Int J Cancer 43, 1083-1090.
14. Newcom SR, Kadin ME, and Phillips C (1988). L-428 Reed-Sternberg cells and mononuclear Hodgkin's cells arise from a single cloned mononuclear cell. Int J Cell Cloning 6, 417-431.
15. Küppers R (2009). The biology of Hodgkin's lymphoma. Nat Rev Cancer 9, 15-27.
16. Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M, et al. (2009). Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 113, 5920-5926.
17. Brousset P, Al Saati T, Chaouche N, Zenou RC, Schlaifer D, Chittal S, and Delsol G (1997). Telomerase activity in reactive and neoplastic lymphoid tissue: infrequent detection of activity in Hodgkin's disease. Blood 89, 26-31.
18. Norrback KF, Enblad G, Erlanson M, Sundström C, and Roos G (1998). Telomerase activity in Hodgkin's disease. Blood 92, 567-573.
19. Heine B, Hummel M, Demel G, and Stein H (1999). Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease overexpress the telomerase RNA template (hTR). J Pathol 188, 139-145.
20. Knecht H, Sawan B, Lichtensztejn D, Lemieux B, Wellinger RJ, and Mai S (2009). The 3D nuclear organization of telomeres marks the transition from Hodgkin to Reed-Sternberg cells. Leukemia 23, 565-573.
21. Knecht H, Sawan B, Lichtensztejn Z, Lichtensztejn D, and Mai S (2010). 3D telomere FISH defines LMP 1 expressing Reed-Sternberg cells as end-stage cells with telomere-poor ghost nuclei. Lab Invest 90, 611-619.
22. Guffei A, Sarkar R, Klewes L, Righolt C, Knecht H, and Mai S (2010). Dynamic chromosomal rearrangements in Hodgkin's lymphoma are due to ongoing three-dimensional nuclear remodeling and breakage-bridge-fusion cycles. Haematologica 95, 2038-2046.
23. Schaefer LH, Schuster D, and Herz H (2001). Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy. JMicrosc 204, 99-107.
24. Vermolen BJ, Garini Y, Mai S, Mougey V, Fest T, Chuang TC, Chuang AY, Wark L, and Young IT (2005). Characterizing the three-dimensional organization of telomeres. Cytometry A 67, 144-150.
25. Poon SS, Martens UM, Ward RK, and Lansdorp PM (1999). Telomere length measuring using digital fluorescence microscopy. Cytometry 36, 267-278.
26. Sarkar R, Guffei A, Vermolen BJ, Garini Y, and Mai S (2007). Alterations of centromere positions in nuclei of immortalized and malignant mouse lymphocytes. Cytometry A 71, 386-392.
27. Kuruvilla J (2009). Standard therapy for advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program, pp. 497-506.
28. Steidl C, Connors JM, and Gascoyne RD (2011). Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 29, 1812-1826.
29. Mathas S, Dörken B, and Janz M (2009). The molecular pathogenesis of classical Hodgkin lymphoma. Dtsch Med Wochenschr 134, 1944-1948.
30. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, and Forero-Torres A (2010). Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363, 1812-1821.
31. Hasenclever D and Diehl V (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. NEnglJMed 339, 1506-1514.
32. Devilard E, Bertucci F, Trempat P, Bouabdallah R, Loriod B, Giaconia A, Brousset P, Granjeaud S, Nguyen C, Birnbaum D, et al. (2002). Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 21, 3095-3102.
33. Steidl C, Farinha P, and Gascoyne RD (2011). Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 96, 186-189.
34. Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, Connors JM, Horsman DE, and Gascoyne RD (2011). Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 116, 418-427.
35. Canioni D, Deau-Fischer B, Taupin P, Ribrag V, Delarue R, Bosq J, Rubio MT, Roux D, Vasiliu V, Varet B, et al. (2009). Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One 4, e6341.
36. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, and Jurlander J (2006). FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107, 52-59.
37. Schaadt M, Fonatsch C, Kirchner H, and Diehl V (1979). Establishment of a malignant, Epstein-Barr-virus (EBV)-negative cell-line from the pleura effusion of a patient with Hodgkin's disease. Blut 38, 185-190.
38. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mücke S, von Kalle C, Fonatsch C, Schaefer HE, et al. (1996). Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 87, 3418-3428.
39. MacLeod RA, Spitzer D, Bar-Am I, Sylvester JE, Kaufmann M, Wernich A, and Drexler HG (2000). Karyotypic dissection of Hodgkin's disease cell lines reveals ectopic subtelomeres and ribosomal DNA at sites of multiple jumping translocations and genomic amplification. Leukemia 14, 1803-1814.
40. Mader A, Brüderlein S, Wegener S, Melzner I, Popov S, Muller-Hermelink HK, Barth TF, Viardot A, and Moller P (2007). U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma. Cytogenet Genome Res 119, 204-210.
41. Knecht H, Brüderlein S, Wegener S, Lichtensztejn D, Lichtensztejn Z, Lemieux B, Moller P, and Mai S (2010). 3D nuclear organization of telomeres in the Hodgkin cell lines U-HO1 and U-HO1-PTPN1: PTPN1 expression prevents the formation of very short telomere including t-stumps. BMC Cell Biol 11, 99.
42. Xu L and Blackburn EH (2007). Human cancer cells harbour T-stumps, a distinct class of extremely short telomeres. Mol Cell 28, 315-327.
43. Obermann EC, Mueller N, Rufle A, Menter T, Mueller-Garamvoelgyi E, Cathomas G, Dirnhofer S, and Tzankov A (2011). Clonal relationship of classical Hodgkin lymphoma and its recurrences. Clin Cancer Res 17, 5268-5274.
44. Roughan JE and Thorley-Lawson D (2009). The intersection of Epstein-Barr virus with the germinal center. J Virol 83, 3968-3976.
45. M'kacher R, Bennaceur-Griscelli A, Girinsky T, Koschielny S, Delhommeau F, Dossou J, Violot D, Leclercq E, Courtier MH, Béron-Gaillard N, et al. (2007). Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers. Int J Radiat Oncol Biol Phys 68, 467-471.